Compare Eli Lilly And Co (LLY) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Paychex, Inc. — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Paychex, Inc. trades at $103.98 (market cap $37.19B). The key difference: Eli Lilly And Co is far larger — about 28× Paychex, Inc.'s market cap, and Paychex, Inc. pays the higher dividend (4.56%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Paychex, Inc. for 56 Days on average.
| LLY | PAYX | |
|---|---|---|
Market Cap | $1.04T | $37.19B |
Volume | 3,064,878 | 3,344,316 |
Sector | Health | Industrials |
52-Week High | $1.28K | $128.59 |
52-Week Low | $799.57 | $85.57 |
Typical Hold Time | 93 Days | 56 Days |
Enterprise Value | $1.09T | $40.87B |
Dividend Yield | 0.59% | 4.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
Paychex (PAYX) trades at $104.46, up 2.87% on the day, showing resilience after recent volatility. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages, while fundamentals remain solid with consistent earnings beats, a 27.35% net income margin, and a forward P/E of 20.73. Recent news highlights strong Q1 2027 results but also concerns over dividend sustainability and labor market exposure.
The outlook is cautiously optimistic, supported by robust profitability and a consensus price target of $111, offering potential upside. Key risks include sensitivity to small business employment trends, high valuation multiples, and investor scrutiny of cash flow allocation. The stock presents a hold case for income-focused investors, balancing dividend yield against growth deceleration concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
